FDA Grants Paxlovid Full Approval but Patients Prefer Ivermectin-Based Multidrug Protocols

By Peter A. McCullough, MD, MPH

Emily Harris, writer for JAMA reported on June 7, 2023, that the US FDA fully approved Paxlovid for the acute ambulatory treatment of COVID-19. Paxlovid is dosed from a bubble pack: 2 tabs nirmatrelvir 300 mg plus 1 tab ritonavir 100 mg taken every 12 hours for 5 days. In the video I remind you that the CDC has a public health advisory on Paxlovid rebound or prolongation of the syndrome. Additionally, I review the issue of drug-drug interactions while taking Paxlovid.

You can see that a recent Twitter poll indicated that despite the FDA approval, 99% of respondents would rather have an ivermectin-based protocol (McCullough Protocol, FLCCC, others) than Paxlovid monotherapy. Listen to the entire update to get familiarized with the McCullough Protocol, particularly the viricidal nasal sprays and OTC bundle which you should have at home and ready to go at the first signs of illness.

Please support the Courageous Discourse Substack so we may serve you with this and many more public health updates and critical analyses.

Harris E. FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment. JAMA. 2023;329(24):2118. doi:10.1001/jama.2023.9925

CDC HEALTH ADVISORY Distributed via the CDC Health Alert Network May 24, 2022, 9:00 AM ET CDCHAN-0467 COVID-19 Rebound After Paxlovid Treatment

McCullough Protocol©: Risk Stratification Prior COVID-19 Infection Must be Noted PETER A. MCCULLOUGH, MD, MPH™ OCT 11, 2022

McCullough Protocol©: Nasal-Oral Viricidal Washes and Gargles Treat the Infection at the Source PETER A. MCCULLOUGH, MD, MPH™ OCT 13, 2022

McCullough Protocol©: Nutraceuticals and Prescription Drugs The Art and Science of Medicine Required to Face a Novel Threat PETER A. MCCULLOUGH, MD, MPH™ OCT 14, 2022